{
  "nctId": "NCT02585778",
  "briefTitle": "Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)",
  "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy",
  "protocolDocument": {
    "nctId": "NCT02585778",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2015-07-08",
    "uploadDate": "2018-03-29T17:03",
    "size": 607806,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02585778/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 517,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2015-10-23",
    "completionDate": "2017-04-03",
    "primaryCompletionDate": "2017-04-03",
    "firstSubmitDate": "2015-10-22",
    "firstPostDate": "2015-10-23"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion criteria:\n\n* Participants diagnosed with Type 1 or Type 2 diabetes at least one year prior to the screening visit (Week -3).\n* Signed written informed consent\n* Participants with type 1 or type 2 diabetes treated with insulin whose LDL-C levels were not adequately controlled with maximally tolerated lipid-modifying therapy\n* LDL-C of 70 mg/dL or greater\n* 18 years of age or more\n* Glycosylated hemoglobin (HbA1c) less than 10%\n* History of cardiovascular disease (including coronary heart disease \\[CHD\\] and/or CHD risk equivalents) and/or at least one additional cardiovascular risk factor\n\nExclusion criteria:\n\n* Not on a stable dose of statin or other lipid modifying therapy for at least 4 weeks prior to screening or from screening to randomization, unless statin intolerant\n* Triglycerides \\>400 mg/dL\n* Estimated glomerular filtration rate (eGFR) \\<15 mL/min/1.73 m² according to the Modification of Diet in Renal Disease (MDRD) equation\n* Currently received or planned to receive renal replacement therapy (for example, hemodialysis)\n* Change in weight of more than 5 kilograms within the prior 2 months\n* Not on a stable dose/regimen of insulin or other antidiabetic drugs for the past 3 months or planned to intensify insulin regimen during the study\n* Not treated with insulin for at least 6 months\n* Planned to start new lipid modifying therapy or change dose of current lipid modifying therapy during the study\n* Body mass index (BMI) \\>45 kg/m² or planned to undergo bariatric surgery, weight loss program, or initiate weight loss drugs during the study\n* History of recent decompensation of diabetes within the prior 2 months (for example, diabetic ketoacidosis)\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis",
        "description": "Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).",
        "timeFrame": "From Baseline to Week 24"
      },
      {
        "measure": "Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)",
        "description": "Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the 'treatment-emergent period' (the time from the first dose of study drug up to the last dose of study drug +70 days).",
        "timeFrame": "From Baseline up to 10 weeks after last study drug administration (maximum of 32 weeks)"
      }
    ],
    "secondary": [
      {
        "measure": "Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis",
        "description": "Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).",
        "timeFrame": "From Baseline to Week 24"
      },
      {
        "measure": "Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis",
        "description": "Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.",
        "timeFrame": "From Baseline to Week 24"
      },
      {
        "measure": "Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis",
        "description": "Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.",
        "timeFrame": "From Baseline to Week 24"
      },
      {
        "measure": "Percent Change From Baseline in Measured LDL-C at Week 12 - ITT Analysis",
        "description": "Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.",
        "timeFrame": "From Baseline to Week 24"
      },
      {
        "measure": "Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis",
        "description": "Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.",
        "timeFrame": "From Baseline to Week 24"
      },
      {
        "measure": "Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24 - ITT Analysis",
        "description": "Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.",
        "timeFrame": "From Baseline to Week 24"
      },
      {
        "measure": "Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis",
        "description": "Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.",
        "timeFrame": "From Baseline to Week 24"
      },
      {
        "measure": "Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis",
        "description": "Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 24 (i.e. up to 21 days after last injection).",
        "timeFrame": "Up to Week 24"
      },
      {
        "measure": "Percentage of Participants Reaching Calculated LDL-C <50 mg/dL (1.3 mmol/L) at Week 24 - On-Treatment Analysis",
        "description": "Adjusted percentages at Week 24 from last observation carried forward (LOCF) approach (for T1DM participants) and multiple imputation approach model (for T2DM participants) including available post-baseline data from Week 4 to Week 24 (i.e. up to 21 days after last injection). The maximum likelihood estimate did not exist as response rate was zero in a treatment group of T1DM participants.",
        "timeFrame": "Up to Week 24"
      },
      {
        "measure": "Percentage of Participants Reaching Calculated Non-HDL-C <100 mg/dL at Week 24 - On-Treatment Analysis",
        "description": "Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 24 (i.e. up to 21 days after last injection).",
        "timeFrame": "Up to Week 24"
      },
      {
        "measure": "Percentage of Participants Reaching Calculated Non-HDL-C <80 mg/dL at Week 24 - On-Treatment Analysis",
        "description": "Adjusted percentages at Week 24 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).",
        "timeFrame": "Up to Week 24"
      },
      {
        "measure": "Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis",
        "description": "Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach for handling of missing data followed by robust regression model. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in the imputation model.",
        "timeFrame": "From Baseline to Week 24"
      },
      {
        "measure": "Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis",
        "description": "Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.",
        "timeFrame": "From Baseline to Week 24"
      },
      {
        "measure": "Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis",
        "description": "Adjusted means and standard errors at Week 24 from multiple imputation approach for handling of missing data followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.",
        "timeFrame": "From Baseline to Week 24"
      },
      {
        "measure": "Percent Change From Baseline in LDL-C Particle Number at Week 24 - ITT Analysis",
        "description": "LDL-C particle number was calculated from lipid subfractions by nuclear magnetic resonance (NMR) spectroscopy. Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.",
        "timeFrame": "From Baseline to Week 24"
      },
      {
        "measure": "Percent Change From Baseline in LDL-C Particle Size at Week 24 - ITT Analysis",
        "description": "LDL-C particle size was calculated from lipid subfractions by NMR spectroscopy. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.",
        "timeFrame": "From Baseline to Week 24"
      },
      {
        "measure": "Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24 - ITT Analysis",
        "description": "Absolute change = HbA1c value at specified weeks minus HbA1c value at baseline.",
        "timeFrame": "Baseline, Weeks 12 and 24"
      },
      {
        "measure": "Absolute Change From Baseline in HbA1c at Weeks 12 and 24 - On-Treatment Analysis",
        "description": "Absolute change = HbA1c value at specified weeks minus HbA1c value at baseline.",
        "timeFrame": "Baseline, Weeks 12 and 24"
      },
      {
        "measure": "Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 12 and 24 - ITT Analysis",
        "description": "Absolute change = FPG value at specified weeks minus FPG value at baseline.",
        "timeFrame": "Baseline, Weeks 12 and 24"
      },
      {
        "measure": "Absolute Change From Baseline in FPG at Weeks 12 and 24 - On-Treatment Analysis",
        "description": "Absolute change = FPG value at specified weeks minus FPG value at baseline.",
        "timeFrame": "Baseline, Weeks 12 and 24"
      },
      {
        "measure": "Absolute Change From Baseline in Total Daily Insulin Dose at Weeks 12 and 24 - ITT Analysis",
        "description": "Absolute change = total daily insulin dose at specified weeks minus baseline value.",
        "timeFrame": "Baseline, Weeks 12 and 24"
      },
      {
        "measure": "Absolute Change From Baseline in Total Daily Insulin Dose at Weeks 12 and 24 - On-Treatment Analysis",
        "description": "Absolute change = total daily insulin dose at specified weeks minus baseline value.",
        "timeFrame": "Baseline, Weeks 12 and 24"
      },
      {
        "measure": "Absolute Change From Baseline in Insulin Daily Dose/Kg at Weeks 12 and 24 - ITT Analysis",
        "description": "Absolute change = daily insulin dose/kg at specified weeks minus baseline value.",
        "timeFrame": "Baseline, Weeks 12 and 24"
      },
      {
        "measure": "Absolute Change From Baseline in Insulin Daily Dose/Kg at Weeks 12 and 24 - On-Treatment Analysis",
        "description": "Absolute change = daily insulin dose/kg at specified weeks minus baseline value.",
        "timeFrame": "Baseline, Weeks 12 and 24"
      },
      {
        "measure": "Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Weeks 12 and 24 - ITT Analysis",
        "description": "Glucose lowering treatment was calculated for non-insulin treatments as one for each unique treatment received and for insulin treatment as one in total for all participants who have taken one or more treatments. Absolute change = number of glucose-lowering treatments at specified weeks minus baseline value.",
        "timeFrame": "Baseline, Weeks 12 and 24"
      },
      {
        "measure": "Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Weeks 12 and 24 - On-Treatment Analysis",
        "description": "Glucose lowering treatment was calculated for non-insulin treatments as one for each unique treatment received and for insulin treatment as one in total for all participants who have taken one or more treatments. Absolute change = number of glucose-lowering treatments at specified weeks minus baseline value.",
        "timeFrame": "Baseline, Weeks 12 and 24"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 26,
      "otherCount": 0,
      "totalCount": 28
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:08.741Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}